SPY313.78-3.27 -1.03%
DIA259.04-3.96 -1.51%
IXIC10,343.89-89.76 -0.86%

Barclays Downgrades Biogen to Equal-Weight, Lowers Price Target to $280

Barclays analyst Carter Gould downgrades Biogen (NASDAQ:BIIB) from Overweight to Equal-Weight and lowers the price target from $370 to $280.

Benzinga · -
Barclays analyst Carter Gould downgrades Biogen (NASDAQ: BIIB) from Overweight to Equal-Weight and lowers the price target from $370 to $280.